Targeting epigenetic regulators to overcome drug resistance in cancers

HIGHLIGHTS

• who: Nan Wang from the Originally developed as a MAO inhibitor to treat mood and anxiety disorders, tranylcypromine (TCP) can inhibit the activity of MAO-A and MAO-B [242, ]In addition, as an irreversible , inhibitor, TCP also inhibits cancer proliferation andA clinical phase I/II study investigating whether TCP could sensitize ATRA in patients with non-, AML or MDS in , was initiated by Michael Luebbert and the University Hospital Freiburg (ClinicalTrials.gov Identifier: NCT02717884). In phase I trial, four dose levels of TCP (, mg, mg, mg, mg on days, ) were examined in combination with fixed dose . . .
  

   

  

  If you want to have access to all the content you need to log in!

  Thanks :)

  Username or E-mail:

  If you don't have an account, you can create one here.